Discover more from FarmaKology’s Substack
FarmaKology-New Genomics Technology Could Power Gene Therapy in Oncology
Panavance Therapeutics Inc.
Panavance Therapeutics Inc. is a clinical-stage pharmaceutical company established in 2021 by Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie, in order to advance the development of GP-2250, a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them.With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world. To date, our therapeutic has demonstrated substantial efficacy and safety in extensive preclinical studies, and its early clinical results have been encouraging. Panavance has developed a clear pathway to US registration of GP-2250 for pancreatic cancer.
Pfizer Inc. and ReViral Ltd. announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).
Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
The European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union. Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule
Jazz Pharmaceuticals plc and Werewolf Therapeutics, Inc. today announced that the companies have entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE™ molecule.
IAVI and Moderna partner to tackle broad global health priorities using mRNA for vaccines and antibodies
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and the nonprofit scientific research organization IAVI today announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats. These diseases - HIV/AIDS, tuberculosis (TB), antimicrobial-resistant enteric infections, and COVID-19 - are estimated to have caused at least 95 million new infections and more than 4 million deaths in 2020 alone. The collaboration combines the power of Moderna's mRNA platform and IAVI's expertise in discovery and product development to advance vaccines and antibodies designed to be globally accessible, especially in low-income countries where the targeted diseases have high incidence and prevalence.